Associated Papers
Targeting G1-S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors.
Singh S et al.
Nature, 2025
40836083 (PubMed )
Supplement: 41586_2025_9433_MOESM4_ESM.zip › 2024-07-15654B-s4 › Table_S5_052925.xlsx › Tab_7-zscore_CDK2_A_G
Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity.
Pratt DJ et al.
Journal of Medicinal Chemistry, 2006
Identification of residues in fission yeast and human p34cdc2 required for S-M checkpoint control.
Basi G et al.
Genetics, 1996
Select a paper to view details